Details for Patent: RE44638
✉ Email this page to a colleague
Which drugs does patent RE44638 protect, and when does it expire?
Patent RE44638 protects ZYDELIG and is included in one NDA.
This patent has forty-six patent family members in twenty countries.
Summary for Patent: RE44638
Title: | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Abstract: | The invention provides a class of substituted quinazolinone compounds and methods of treating diseases mediated by PI3K.delta. activity. The disclosed compounds are useful in treating diseases such as bone-resorption disorders; and cancer, especially hematopoietic cancers, lymphomas, multiple myelomas and leukemia. The compounds are also useful in disrupting or inhibiting cellular processes such as leukocyte function or accumulation, neutrophils function, lymphocyte proliferation, and endogenous immune responses. |
Inventor(s): | Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Sammamish, WA), Kesicki; Edward A. (Bothell, WA), Ooi; Hua Chee (Kirkland, WA), Oliver; Amy (Bothell, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA), Puri; Kamal Deep (Lynnwood, WA) |
Assignee: | ICOS Corporation (Indianapolis, IN) |
Application Number: | 13/730,256 |
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent RE44638
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | ZYDELIG | idelalisib | TABLET;ORAL | 205858-001 | Jul 23, 2014 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Gilead Sciences Inc | ZYDELIG | idelalisib | TABLET;ORAL | 205858-002 | Jul 23, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: RE44638
PCT Information | |||
PCT Filed | May 12, 2005 | PCT Application Number: | PCT/US2005/016778 |
PCT Publication Date: | December 01, 2005 | PCT Publication Number: | WO2005/113556 |
International Family Members for US Patent RE44638
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2005245875 | ⤷ Try a Trial | |||
Australia | 2009230739 | ⤷ Try a Trial | |||
Canada | 2566609 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |